Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
On December 1, 2022, DTRT Health Acquisition Corp., a Delaware corporation (we, us, our, or the
Company), convened and then adjourned, without conducting any other business, the special meeting of stockholders originally scheduled for December 1, 2022 (the Special Meeting). The only proposal submitted
for a vote of the stockholders at the Special Meeting was the approval of the adjournment of such meeting to December 6, 2022 at 3:00 p.m. Central Time (the Adjournment Proposal). The Adjournment Proposal is described in greater
detail in the definitive proxy statement of DTRT, which was filed with the Securities and Exchange Commission (the SEC) on October 31, 2022 (the Proxy Statement).
As of the close of business on October 24, 2022, the record date for the Special Meeting, there were 23,000,000 shares of Class A common stock, par
value $0.0001 per share (Class A common stock), 5,750,000 shares of Class B common stock, par value $0.0001 per share (the Class B common stock, and together with Class A common stock, the common
stock), outstanding. Each share of common stock was entitled to one vote on the Adjournment Proposal. The shares of Class A common stock and Class B common stock were voted as a single class. A total of 22,658,616 shares of
common stock, representing approximately 78.8% of the outstanding shares of common stock entitled to vote, were present in person or by proxy, constituting a quorum to conduct business.
The Companys stockholders approved the adjournment proposal by the votes set forth below:
|
|
|
|
|
For |
|
Against |
|
Abstain |
22,134,219 |
|
512,357 |
|
20,308 |
Item 7.01 |
Regulation FD Disclosure. |
Furnished as Exhibit 99.1 hereto is a press release, dated December 1, 2022 (the Press Release), issued by DTRT announcing that DTRT convened
and then adjourned, without conducting any other business, the Special Meeting. The Special Meeting has been adjourned until December 6, 2022 at 3:00 p.m. Central Time.
The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise be subject to liabilities under that section, and shall not be deemed to be incorporated by reference into any filings of the Company under the Securities of
1933, as amended (the Securities Act), or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K (the Current Report)
shall not be deemed an admission as to the materiality of any information in this Item 7.01, including Exhibit 99.1.
About DTRT Health Acquisition
Corp.
DTRT Health Acquisition Corp. is a special purpose acquisition company formed for the purpose of entering into a business combination. Its
objective is to acquire a healthcare company that is poised for rapid growth amid todays evolving healthcare landscape and that will capitalize on the fragmented nature of the industry to drive accretive consolidation. Its securities are
listed on Nasdaq under the tickers DTRT, DTRTU and DTRTW. DTRT is led by Mark Heaney, Chief Executive Officer and Executive Chairman, Arion Robbins, Chief Operating Officer and Don Klink, Chief Financial Officer.
Additional Information and Where to Find It
The
definitive proxy statement has been mailed to the Companys stockholders. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT MATERIALS BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE
COMPANY. Investors